Patenting of a Drug Under IPR.
Introduction This particular blog is on the subject matter that how a drug patent can be obtained under the patent law in India and in this context the landmark judgement of the Supreme court- Novartis v. Union of India has been covered in this blog. In this blog the various facets with respect to getting […]
Pharma Companies Extend Patent Life With Slight Modifications
Introduction The pharmaceutical industry is one of the most potential industry which has huge profit margins. Extensive growth and knowledge are required with frequent changes for better technology and results. Starting from early to the final stage there are gigantic chances of the product’s to face success or failure. Apart from these challenges, a large […]
Unboxing The Confusion In Marks Of Pharmaceutical Products
It is not new that the Supreme Court had cautiously laid down the seven principles for determining confusion or deceptiveness in pharmaceutical products. The landmark case of Cadilla held that medicines are boon but if given wrongly it can have life-threatening impact. Thus, there need not be an iota of confusion in the mind of […]
Successful Completion of International Patent Drafting Competition 2017
IIPRD, along with Khurana & Khurana, Advocates and IP Attorneys (K&K) and its eminent foreign associates, conducted Third edition of International Patent Drafting Competition (IPDC). IPDC was designed with an objective to test acumen and skill set of various practitioners pertaining to patent drafting that forms a critical part in patent lifecycle. IPDC aims to encourage people […]
Injunction against Cipla COPD Drug ‘INDAFLO’ Upheld: Delhi High Court
Reportedly, on an appeal filed by Cipla pertaining to COPD drug INDAFLO, the Delhi High court division bench maintained the interim injunction imposed by single judge against Cipla. As per the order, Cipla has now been restrained from, inter alia, using, manufacturing, importing, selling any pharmaceutical products etc. containing ‘INDACATEROL‘ or ‘INDACATEROL Maleate‘, alone or […]
Analysis of the rejection of Lumacaftor (Polymorph) patent application in India
We have been receiving requests from our Pharma clients/readers of the blog for the analysis of the decision/ facts that led to rejection of Lumacaftor (Polymorph) patent application in India since last year. Here is our take: Details of the Patent Application and important dates: Patent application number in India 2056/KOLNP/2010 Title of the invention […]